Slide 1: Aroa Biosurgery September Quarterly (Q2 FY24) Report
For personal use only AROA BIOSURGERY (ARX) SEPTEMBER QUARTERLY (Q2 FY24)REPORT Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 31st October 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a gener
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM™ platform families for new products, line >US$3b1 TAM predominantly sold to US extensions & enables AROA’s hospitals for existing products tissue apposition platform US Direc
Slide 4: AROA ECM – Structure & Biology for Regenerative Healing
|4 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenes
Slide 5: AROA ECM - restores functional tissue
|5 AROA ECM - restores functional tissue For personal use only 96 PRESENTATIONS/ 46 PRESENTATIONS/ 37 PRESENTATIONS/ PUBLICATIONS PUBLICATIONS PUBLICATIONS Volumetric fill- Rapid Tolerated in No negative formation of well contaminated field, inflammatory vascularized and resistant to infection3,5 re
Slide 6: Q2 Financial highlights
|6 Q2 Financial highlights Cash receipts from customers for the quarter of NZ$14.8 million. For personal use only Net cash outflows from operations was NZ$3.2 million, reduced by NZ$1.6 million from the previous quarter Net cash outflow from investing activities was NZ$1.2 million for the quarter, r
Slide 7: Maintaining FY24 Guidance
|7 Maintaining FY24 Guidance For personal use only NZ$72-75m 85% NZ$1-2m Product Revenue (YoY CC Product Gross Margin Normalised EBITDA growth 25 – 30%) Total revenue ~ NZ$73-76m All guidance is presented on a constant currency ('CC') basis using a NZ$/US$ exchange rate of 0.65, compared to the aver
Slide 8: AROA sales growth
|8 AROA sales growth Validating and optimizing the sales model • 10 field sales reps average run rate >US$750,000 p.a. (vs 8 (Q1’24), 5 (Q4’23)) & 50% > US$250,000 p.a. • Myriad sales continued to grow, 67% of AROA’s direct sales mix (vs. 50% pcp). For personal use only 2020 - 2022 2023 - 2024 Focus
Slide 9: Enivo – tissue apposition platform
|9 Enivo – tissue apposition platform Expected to improve the rate and quality of tissue healing with fewer complications For personal use only • Enivo pump and catheter, key components of the Enivo Tissue Apposition Platform are US FDA 510(k) cleared. • In August submitted a US FDA 510(k) submissio
Slide 10: Clinical Research
| 10 Clinical Research “Ovine Forestomach Matrix in the Surgical Management of Complex Volumetric Soft Tissue Defects: A Retrospective Pilot Case Series”. For personal use only • Retrospective case series (n = 13 defects) evaluated the clinical effectiveness of Myriad in the surgical management of c
Slide 11: Clinical Research
| 11 Clinical Research Projects Initiatives FY2024 FY2025 FY2026 For personal use only • Prospective observation registry Registry • N=300 complex soft tissue reconstructions (225 recruited) • N=10 US sites (9 sites operational) Pivotal • Prospective intervention Myriad/NPWT study in acute Study rec
Slide 12: Manufacturing and Production
| 12 Manufacturing and Production Well established commercial manufacturing facility In September, following its annual audit by DEKRA, AROA was re-certified for compliance to ISO 13485 and for the Medical Device Single Audit Program. For personal use only Unique process produces a Scalable high-qua
Slide 13: FY24 Catalysts
| 13 FY24 Catalysts For personal use only Post-COVID TELA Bio Sales TELAFDA Enivo Bio clearance Sales AROA Sales Momentum Momentum Momentum COVID-19 expected to have a reduced Parallel initiatives being progressed to impact for remainder of FY23 Clinicalexpedite outcomes FDA& clearance cost savings
Slide 14: Q&A
? For personal use only Q&A Unlocking regenerative healing for everybody
Slide 15: Contact
CONTACT For personal use only James Agnew m +64 21 744 915 investor@aroabio.com Visit our website www.aroa.com and find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2150, Auckland 2022, New Zealand New Zealand